Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease

References

• Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma. Science. 1994;266(5192):1865–12. doi:10.1126/science.7997879.
   PubMed Web of Science ®Google Scholar
• Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186–1191. doi:10.1056/NEJM199505043321802.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Wang V, O’Mahony D, Aleman K, Wyvill K, Marshall V, Steinberg S, Pittaluga S, Maric I, Whitby D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis. 2010;51(3):350–358. doi:10.1086/654798.
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric castleman’s disease. Blood. 1995;86(4):1276–1280. doi:10.1182/blood.V86.4.1276.bloodjournal8641276.
   PubMed Web of Science ®Google Scholar
• Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome. Front Microbiol. 2012;3:73. doi:10.3389/fmicb.2012.00073.
   PubMed Web of Science ®Google Scholar
• Narkhede M, Arora S, Ujjani C. Primary effusion lymphoma: current perspectives. Onco Targets Ther. 2018;11:3747–3754. doi:10.2147/OTT.S167392.
   PubMed Web of Science ®Google Scholar
• Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill K, Goncalves P, Ramaswami R, Marshall V, Miley W, Steinberg S, et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 2019;133(16):1753–1761. doi:10.1182/blood-2019-01-893339.
   PubMed Web of Science ®Google Scholar
• Lurain K, Ramaswami R, Widell A, Ekwede I, Mangusan R, George J, Jaffe ES, Pittaluga S, Stetler-Stevenson M, Roth M, et al. Phase I study of lenalidomide combined with dose-adjusted EPOCH and Rituximab (EPOCH-R2) in primary effusion lymphoma in participants with or without HIV (NCT02911142). Blood. 2020;136(Supplement 1):8–9. doi:10.1182/blood-2020-137188.
   PubMedGoogle Scholar
• Hu Z, Pan Z, Chen W, Chi Y, Wang W, Yuan J, Wang E, Zhang S, Kurt H, Mai B, et al. Primary effusion lymphoma: a clinicopathological study of 70 Cases. Cancer (Basel). 2021;13(4): 878. doi:10.3390/cancers13040878.
   PubMed Web of Science ®Google Scholar
• Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol. 2018;9:2722. doi:10.3389/fimmu.2018.02722.
   PubMed Web of Science ®Google Scholar
• Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF, Lee HC. (1993). Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science, 262(5136), 1056–9. 10.1126/science.8235624
   PubMed Web of Science ®Google Scholar
• Cesano A, Visonneau S, Deaglio S, Malavasi F, Santoli D. Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells. J Immunol. 1998;160:1106–1115.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, Dianzani U, Stockinger H, Malavasi F. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. 1998;160:395–402.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848. doi:10.4049/jimmunol.1003032.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, van Egmond M, van Bueren JJL, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321. doi:10.1080/19420862.2015.1007813.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RWJ, Parren PWHI, Leusen JHW, Boross P. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcgamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807–813. doi:10.4049/jimmunol.1501351.
   PubMed Web of Science ®Google Scholar
• Dima D, Dower J, Comenzo RL, Varga C. Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res. 2020;12:7891–7903. doi:10.2147/CMAR.S212526.
   PubMed Web of Science ®Google Scholar
• Karakasheva TA, Waldron TJ, Eruslanov E, Kim S-B, Lee J-S, O’Brien S, Hicks PD, Basu D, Singhal S, Malavasi F, et al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res. 2015;75(19):4074–4085. doi:10.1158/0008-5472.CAN-14-3639.
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, Mauri C. CD19 + CD24 hi CD38 hi B cells maintain regulatory T cells while limiting T H 1 and T H 17 differentiation. Sci Transl Med. 2013;5(173):173ra123. doi:10.1126/scitranslmed.3005407.
   Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NWCJ, Weiss BM, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi:10.1182/blood-2015-12-687749.
   PubMed Web of Science ®Google Scholar
• Shrestha P, Davis DA, Veeranna RP, Carey RF, Viollet C, Yarchoan R. Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. PLoS Pathog. 2017;13(9):e1006628. doi:10.1371/journal.ppat.1006628.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe JA, Marti G, Menozzi D, Oldaker TA, Matos AOD, Rabellino E, et al. Clinical flow cytometric analysis of neoplastic hematolymphoid cells; approved guideline. H43-A2. Vol. 11 (ed 2nd). Wayne (PA): Clinical and Laboratory Standards Institute; 2007.
   Google Scholar
• Davis DA, Shrestha P, Aisabor AI, Stream A, Galli V, Pise-Masison CA, Tagawa T, Ziegelbauer JM, Franchini G, Yarchoan R . Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. Oncoimmunology. 2019;8(2):e1546544. doi:10.1080/2162402X.2018.1546544.
   PubMed Web of Science ®Google Scholar
• Matas-Cespedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, et al. The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(6):1493–1505. doi:10.1158/1078-0432.CCR-15-2095.
   PubMed Web of Science ®Google Scholar
• CE SSH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. ed 4th. Lyon (France). IARC Publication. 2017.
   Google Scholar
• Galán J, Martin I, Carmona I, Rodriguez‐Barbero JM, Cuadrado E, García‐Alonso L, García‐Vela JA. The utility of multiparametric flow cytometry in the detection of primary effusion lymphoma (PEL). Cytometry B Clin Cytom. 2019;96(5):375–378. doi:10.1002/cyto.b.21637.
   PubMed Web of Science ®Google Scholar
• Clemens PL, Yan X, Lokhorst HM, Lonial S, Losic N, Khan I, Jansson R, Ahmadi T, Lantz K, Zhou H, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2017;56(8):915–924. doi:10.1007/s40262-016-0477-1.
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383–3389. doi:10.1182/blood.V98.12.3383.
   PubMed Web of Science ®Google Scholar
• Guc D, Canpinar H, Kucukaksu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur J Haematol. 2000;64(1):3–9. doi:10.1034/j.1600-0609.2000.80097.x.
   PubMed Web of Science ®Google Scholar
• Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18(4):1039–1050. doi:10.1158/1078-0432.CCR-11-1429.
   PubMed Web of Science ®Google Scholar
• Varela JC, Atkinson C, Woolson R, Keane TE, Tomlinson S. Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer. 2008;123(6):1357–1363. doi:10.1002/ijc.23676.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RWJ, van Duin M, Sonneveld P, Minnema MC, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959–970. doi:10.1182/blood-2016-03-703439.
   PubMed Web of Science ®Google Scholar
• Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma. 2008;8(5):300–304. doi:10.3816/CLM.2008.n.042.
   PubMedGoogle Scholar
• Lurain K, Ramaswami R, Widell A, Ekwede I, George J, Stetler-Stevenson M, Raffeld M, Yuan CM, Ziegelbauer J, Maldarelli F, et al. Phase I/II study of lenalidomide combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in primary effusion lymphoma in patients with or without HIV. Blood. 2019;134(Supplement_1):4096. doi:10.1182/blood-2019-122070.
   Google Scholar
• Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039–2049. doi:10.1038/leu.2015.123.
   PubMed Web of Science ®Google Scholar
• Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020;34(3):938–941. doi:10.1038/s41375-019-0587-5.
   PubMed Web of Science ®Google Scholar
• Davis DA, Mishra S, Anagho HA , Aisabor AI, Shrestha P, Wang V, Takamatsu Y, Maeda K, Mitsuya H, Zeldis JB, et al. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget. 2017;8(31):50342–50358. doi:10.18632/oncotarget.17960.
   PubMedGoogle Scholar
• Shrestha P, Davis DA, Jaeger HK, Stream A, Aisabor AI, Yarchoan R. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2. PLoS Pathog. 2021;17(1):e1009091. doi:10.1371/journal.ppat.1009091.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan R, Matta H, Tolani B, Triche Jr T Jr., Chaudhary PM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016;35(14):1797–1810. doi:10.1038/onc.2015.245.
   PubMed Web of Science ®Google Scholar
• Pierpont TM, Limper CB, Richards KLP. Present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. doi:10.3389/fonc.2018.00163.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, Wyvill KM, Marshall V, Whitby D, Wang V, Pittaluga S, O’Mahony D, Steinberg SM, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124(24):3544–3552. doi:10.1182/blood-2014-07-586800.
   PubMed Web of Science ®Google Scholar
• Lurain K, Yarchoan R, Uldrick TS. Treatment of kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):75–88. doi:10.1016/j.hoc.2017.09.007.
   PubMed Web of Science ®Google Scholar
• Panaampon J, Kariya R, Okada S . Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. Cancer Immunol Immunother. 2022;71(5):1017–1031. doi:10.1007/s00262-021-03054-8.
   PubMed Web of Science ®Google Scholar
• Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol. 1991;146:2345–2351.
   PubMed Web of Science ®Google Scholar
• Huang J, Gou D, Zhen C, Jiang D, Mao X, Li W, Chen S, Cai C. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP. FEMS Immunol Med Microbiol. 2001;31(3):203–209. doi:10.1111/j.1574-695X.2001.tb00521.x.
   PubMedGoogle Scholar
• Mamidi S, Hone S, Teufel C, Sellner L, Zenz T, Kirschfink M. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology. 2015;4(3):e979688. doi:10.4161/2162402X.2014.979688.
   PubMed Web of Science ®Google Scholar
• Shah NN, Singavi AK, Harrington A. Daratumumab in Primary Effusion Lymphoma. N Engl J Med. 2018;379(7):689–690. doi:10.1056/NEJMc1806295.
   PubMed Web of Science ®Google Scholar
• Wiltshire K, Kliman D, Tan J, Quach H, Kalff A, Cameron R, Grigoriadis G, Nandurkar H. Daratumumab as first line therapy in primary effusion lymphoma: a case report. Ann of Lymphoma. 2021;5:33. doi:10.21037/aol-21-26.
   Google Scholar
• Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, Gong J-N, Huntington ND, Shi W, Huang DCS, et al. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018;132(20):2166–2178. doi:10.1182/blood-2018-05-850727.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, Munshi NC, Tai YT, Anderson KC. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate in multiple Myeloma. Clin Cancer Res. 2017;23(15):4290–4300. doi:10.1158/1078-0432.CCR-16-3192.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, Boise LH, Lonial S. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer. 2019;125(17):2991–3000. doi:10.1002/cncr.32178.
   PubMed Web of Science ®Google Scholar
• Cho A, Jantschitsch C, Knobler R. Extracorporeal photopheresis-an overview. Front Med (Lausanne). 2018;5:236. doi:10.3389/fmed.2018.00236.
   PubMed Web of Science ®Google Scholar
• Iselin C, Chang YT, Schlaepfer T, Fassnacht C, Dimitriou F, Nägeli M, Pascolo S, Hoetzenecker W, Bobrowicz M, Guenova E. Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome. Oncoimmunology. 2021;10(1):1873530. doi:10.1080/2162402X.2021.1873530.
   PubMed Web of Science ®Google Scholar
• Iniesta P, Revilla N, Chen-Liang TH, Hurtado AM, Vicente V, Heras I, Jerez A, Lozano ML. An early increase of CD56 bright natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graft-versus-host disease. Transfusion. 2018;58(12):2924–2932. doi:10.1111/trf.14964.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Lammerts van Bueren JJ, van Kessel B, Andre P, Morel Y, Lokhorst HM, van de Donk NWCJ, Parren PWHI, Mutis T. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015;100(2):263–268. doi:10.3324/haematol.2014.117531.
   PubMed Web of Science ®Google Scholar
• Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, et al. A pilot trial of lirilumab with or without azacitidine for patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2018;18(10):658–663.e652. doi:10.1016/j.clml.2018.06.011.
   PubMed Web of Science ®Google Scholar
• Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H, et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell. 2021;28(12):2062–2075.e2065.
   PubMed Web of Science ®Google Scholar